The FDA has accepted the NDA for paltusotine for the treatment and long-term maintenance of acromegaly in adults.

Paltusotine was granted Orphan Drug Designation for the treatment of acromegaly by the FDA in July 2020. This designation is provided to drugs defined as being intended for the safe and effective ...

Patients with acromegaly make too much growth hormone, which causes them to grow disproportionately large bones, organs and ...

Acromegaly is a serious endocrine disease associated ... including biochemical discrepancies, adverse effects of drugs and slowly developing recurrence). Such patients will, therefore, exhibit ...

In Phase 3 studies, once-daily, oral paltusotine maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1 ...

Sandostatin (octreotide acetate) is a prescription drug used to treat acromegaly and other conditions. Sandostatin can cause side effects that range from mild to serious. Examples include diarrhea ...

Pharmaceuticals announced the U.S. Food and Drug Administration, FDA, accepted its New Drug Application, NDA, for ...

Biochemical control of acromegaly in noncured patients is usually defined as serum growth hormone (GH) levels <2.0 µg/l, plus normal-for-age serum levels of insulin-like growth factor I (IGF-I).

The condition, called acromegaly or gigantism, can be successfully treated with brain surgery and medication. Prof Korbonits put Colleen in touch with Brendan Holland from Dungannon, County Tyrone ...